Avandia Monotherapy Use Curtailed in Canada
This article was originally published in The Pink Sheet Daily
Executive Summary
Cardiac safety concerns fuel Health Canada to recommend rosiglitazone as second-line treatment for diabetes.
You may also be interested in...
Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
Benefits Of Avandia, Actos Outweigh Risks – EMEA
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.